Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma

Cho, Sung Woo; Kim, Joon Mo; Park, Ki Ho; Choi, Chul Young

doi:10.1007/s10384-010-0855-4

Cited by 12 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improved adherence has also been reported as compared to the use of either travoprost or timolol separately [11][12][13]. However, as little time has passed since the TTFC and other fixed-combination therapies have been approved for glaucoma, there is as yet little information available on the use of such combination therapies in Asian glaucoma patients, including Japanese patients, compared to the many reports that focus on Caucasian populations [14].…”

Section: Introductionmentioning

confidence: 94%

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Kashiwagi

2012

Jpn J Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 94%

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Kashiwagi

2012

Jpn J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Participants were followed for 6 months Chen 2006 Not a randomized trial: prospective case series of patients switched to unoprostone isopropyl ophthalmic solution (Rescula) after initial treatment with beta-blockers. Participants were followed for 1 year Cho 2010 Short-term trial: evaluation of fixed combination of brimonidine 0.2%-timolol 0.5% in people with glaucoma. Participants were followed for up to 6 months CNTGS 1998 Not intervention of interest: included any medical and surgical treatment to lower IOP, and was not limited to the agents listed in the protocol Cohen 2005 Not a randomized trial: review of ocular hypotensive agents for the treatment of glaucoma and ocular hypertension Cordeiro 2011 Not a randomized trial: editorial discussing clinical trials for neuroprotection in glaucoma Costagliola 2014 Short-term trial: RCT of palmitoylethanolamide versus no palmitoylethanolamide in people with NTG.…”

Section: Appendicesmentioning

confidence: 99%

Neuroprotection for treatment of glaucoma in adults

Sena

Lindsley

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells, and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the most common form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death. Objectives The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults compared with no neuroprotective agent, placebo, or other glaucoma treatment. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 7), Ovid MEDLINE, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to August 2016), Embase (January 1980 to August 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to August 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 August 2016. Selection criteria We included randomised controlled trials (RCTs) in which topical or oral treatments were used for neuroprotection in adults with OAG. Minimum follow-up time was four years. Data collection and analysis Two review authors independently reviewed titles and abstracts from the literature searches. We obtained full-text copies of potentially relevant studies and re-evaluated for inclusion. Two review authors independently extracted data related to study characteristics, risk of bias, and outcomes. We identified one trial for this review, thus we performed no meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until study investigators provide additional study details. We documented reasons for excluding studies from the review. Main results We included one multicenter RCT of adults with low-pressure glaucoma (Low-pressure Glaucoma Treatment Study, LoGTS) conducted in the USA. The primary outcome was progression of visual field loss after four years of treatment with either brimonidine or timolol. Of the 190 adults enrolled in the study, the investigators excluded 12 (6.3%) after randomization; 77 participants (40.5%) did not complete four years of follow-up. The rate of attrition was unbalanced between groups with more participants dropping out of the brimonidine group (55%) than the timolol group (29%). Of those remaining in the study at four years, participants assigned to brimonidine showed less progression of visual field loss than participants assigned to tim...

show abstract

“…Cho et al [34] reported that after instillation with one drop of brimonidine/timolol fixed combination, the largest difference in IOP between treated and untreated eyes 6 hours after instillation was 1.7 mmHg ( p = 0.011). Differences in IOP between instilled eyes and untreated eyes first appeared 4 hours after instillation and were maintained for 14 hours after instillation.…”

Section: Discussionmentioning

confidence: 99%

“…Differences in IOP between instilled eyes and untreated eyes first appeared 4 hours after instillation and were maintained for 14 hours after instillation. However, Cho et al [34] did not measure IOP later than 14 hours after instillation. In the present study, the largest difference in IOP between treated and untreated eyes 8 hours after instillation was 1.67 mmHg in the BTFC group ( p < 0.001).…”

Section: Discussionmentioning

confidence: 99%

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects

Shim

Kim

Choi

et al. 2014

Korean J Ophthalmol

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate the effects of a bimatoprost/timolol fixed combination (BTFC) and a latanoprost/timolol fixed combination (LTFC) on diurnal intraocular pressure (IOP) and anterior ocular parameters in healthy subjects.MethodsWe enrolled 58 healthy subjects in this prospective clinical study. Thirty subjects were treated with BTFC and 28 subjects were treated with LTFC. IOP was measured every 2 hours except from 01:00 and 05:00. Axial length, corneal curvature, and anterior chamber depth were obtained using the IOL master at baseline and 24 hours later. Adverse events were assessed by patient interview and by slit lamp examination.ResultsThe largest difference in IOP between treated and untreated eyes 8 hours after instillation was 1.67 mmHg in the BTFC group (p < 0.001). The largest difference in IOP between treated and untreated eyes 10 hours after instillation was 1.93 mmHg in the LTFC group (p < 0.001). For anterior ocular parameters such as axial length, corneal curvature, anterior chamber depth at baseline and 24 hours after instillation, there were no significant differences between the baseline and 24-hour values in either the BTFC or LTFC group. The most frequently occurring adverse event was conjunctival hyperemia, which was found in 33.3% (n = 10) of the BTFC group and 25.0% (n = 7) of the LTFC group (p = 0.486).ConclusionsBTFC and LTFC provided a significant reduction in IOP from baseline without changing any anterior ocular parameters. Our results provide a reference for monocular trials to assess the effect of eye drops in a clinical condition.

show abstract

Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma

Abstract: The results of this study suggest that brimonidine/timolol fixed-combination therapy has beneficial IOP-lowering effects and significant effects on pupil size.

Cited by 12 publications

References 31 publications

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Neuroprotection for treatment of glaucoma in adults

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects

Contact Info

Product

Resources

About